Human progress has always been constrained by two ancient and stubborn forces: poor health and economic disparity. These are not separate problems — they are deeply intertwined, and they compound across generations. Critical Mass Ventures addresses both through philanthropic giving and strategic investment, with a particular interest in funding novel, creative, and multidisciplinary ideas.
The twentieth century witnessed one of the most consequential achievements in human history: a 30-year gain in life expectancy, driven primarily by the conquest of infectious disease through antibiotics, vaccines, and improvements in public health infrastructure. Parallel advances in molecular medicine — the development of insulin therapy, the elucidation of lipid metabolism pathways that enabled statins, and more recently the therapeutic harnessing of GLP-1 receptor biology — transformed once-fatal conditions into manageable ones, extending both survival and quality of life for hundreds of millions of people.
Yet these gains have not translated into a corresponding expansion of healthspan. Globally, the gap between lifespan and healthy life expectancy now stands at 9.6 years, rising to 12.4 years in developed nations and 2.4 years wider for women than for men. Approximately 20% of adult life is now lived with significant morbidity: 85% of adults over 65 carry at least one chronic condition, and 60% carry two or more. Rather than the compression of morbidity toward the end of life that was anticipated as a natural consequence of medical progress, the 21st century is witnessing its expansion.
The biological determinants of this gap remain incompletely understood. Aging itself is not a single process but an ensemble of interacting hallmarks — among them cellular senescence, mitochondrial dysfunction, proteostatic decline, epigenetic dysregulation, and chronic low-grade inflammation — whose relative contributions to disease onset and functional decline vary across tissues, individuals, and populations. Disentangling these mechanisms, identifying the interventions that meaningfully modify them, and navigating the complex translational pathway from experimental model to clinical application represent defining scientific challenges of our time.
Regional and demographic variation in healthspan outcomes suggests that the gap is not fixed — some populations maintain health and functional independence far closer to the end of life than others, implying that biological, behavioral, and structural factors all contribute, and that systematic intervention holds genuine promise.
Critical Mass Ventures is committed to funding the science and the scientists working at this frontier — advancing mechanistic understanding, supporting rigorous translational research, and ensuring that the benefits of emerging healthspan interventions reach the populations that need them most.
The Healthspan Imperative RFADespite the abundance of wealth that exists in the world today, economic disparity remains a persistent and deeply entrenched reality. While the causes are numerous, issues such as financial exclusion are both preventable and solvable. Access to basic financial services (such as banking, payments, credit, insurance and safe investments) and the knowledge to use them effectively, should be a universal baseline, not a privilege.
The World Bank estimates that roughly 1.4 billion adults globally remain unbanked, a population disproportionately comprising women, rural communities, and people in low-income countries. The problem is self-reinforcing: poverty makes it harder to access financial systems, and exclusion from those systems makes it harder to escape poverty — a cycle that is difficult to break without deliberate intervention.
Achieving meaningful financial inclusion requires addressing a broad range of interconnected barriers:
We believe that every person, regardless of their circumstances, deserves access to financial services, the knowledge to use them, and the agency to improve their own situation.
While meaningful progress has been made in expanding access to financial services, the benefits have been reaped disproportionately by those with greater means. We are committed to funding innovative research and solutions that rise to the challenge of providing ethical and sustainable financial solutions to the under-banked and under-privileged.
If you are working in the area of financial inclusion — whether as a researcher, practitioner, technologist, or policy innovator — we want to hear from you. Critical Mass Ventures is actively seeking to collaborate with individuals and organizations who are doing serious, impactful work in this space. We are particularly interested in connecting with those whose work bridges the gap between access and meaningful economic participation. Reach out to us at hello@criticalmassventures.co.
A fellowship for late-stage postdoctoral scientists ready to carry their discoveries beyond the laboratory. 4–5 awards of $70,000–$75,000. Deadline: July 1, 2026.